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Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus:
Does Vancomycin Heteroresistance Matter?
Kimberly C. Claeys,a Abdalhamid M. Lagnf,a Jessica A. Hallesy,a Matthew T. Compton,a Alison L. Gravelin,a Susan L. Davis,a,b
Michael J. Rybaka,c
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University,
Detroit, Michigan, USAa; Department of Pharmacy Services, Henry Ford Health-System, Detroit, Michigan, USAb; School of Medicine, Wayne State University,
Detroit, Michigan, USAc

Vancomycin remains the mainstay treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections, including
pneumonia. There is concern regarding the emergence of vancomycin tolerance, caused by heterogeneous vancomycin-intermediate S. aureus (hVISA), and subsequent vancomycin treatment failure. Pneumonia is associated with high morbidity and mortality, especially with delays in appropriate therapy. This study evaluated the clinical outcomes of patients with hVISA pneumonia compared to those with vancomycin-susceptible S. aureus (VSSA) pneumonia. A retrospective cohort of patients with MRSA
pneumonia from 2005 to 2014 was matched at a ratio of 2:1 VSSA to hVISA infections to compare patient characteristics, treatments, and outcomes. hVISA was determined by the 48-h population analysis profile area under the curve. Characteristics between VSSA and hVISA infections were compared by univariate analysis and multivariable logistic regression analysis to determine independent risk factors of inpatient mortality. Eighty-seven patients were included, representing 29 hVISA and 58 VSSA
cases of pneumonia. There were no significant differences in demographics or baseline characteristics. Sequential organ failure
assessment (SOFA) scores were a median of 7 (interquartile ratio [IQR], 5 to 8) in hVISA patients and 5 (IQR, 3 to 8) in VSSA
(P ⴝ 0.092) patients. Inpatient mortality was significantly higher in hVISA patients (44.8% versus 24.1%; P ⴝ 0.049). Predictors
of inpatient mortality upon multivariable regression were SOFA score (adjusted odds ratio [aOR], 1.36; 95% confidence interval
[CI], 1.08 to 1.70), Panton-Valentine leukocidin (PVL) positivity (aOR, 6.63; 95% CI, 1.79 to 24.64), and hVISA phenotype (aOR,
3.95; 95% CI, 1.18 to 13.21). Patients with hVISA pneumonia experienced significantly higher inpatient mortality than those
with VSSA pneumonia. There is a need to consider the presence of vancomycin heteroresistance in pneumonia caused by MRSA
in order to potentially improve clinical outcomes.

L

ower respiratory tract infections (LRTIs), in particular, pneumonias, are a major cause of morbidity and mortality. The
Centers for Disease Control and Prevention (CDC) report pneumonia to be the leading cause of infection-related death (1). The
Extended Prevalence of Infection in Intensive Care (EPIC) II
point prevalence study of 1,265 intensive care units (ICUs) across
Europe found that respiratory infections accounted for more than
50% of all culture-positive patients, with the most common
Gram-positive organism being Staphylococcus aureus (2). Additionally, the National Healthcare Safety Network at the CDC
reported S. aureus to be the number one cause of ventilator-associated pneumonia (VAP) in a nationwide survey of health careassociated infections (3). Adding to the clinical dilemma, several
publications have linked delays in appropriately targeted therapy
to increased mortality, especially in critically ill patients with VAP
(4–7).
Methicillin-resistant S. aureus (MRSA) is a common causative
organism in pneumonia, particularly health care-associated pneumonia (HCAP) and hospital-acquired pneumonia (HAP) (8, 9).
Vancomycin is the primary treatment for infections caused by
MRSA, including pneumonia. Continued selective pressure, however, has led to tolerant and resistant strains, such as vancomycinintermediate S. aureus (VISA) and vancomycin-resistant S. aureus, which has compromised the utility of this agent (10, 11). Of
particular clinical concern is heterogeneous vancomycin-intermediate S. aureus (hVISA) as it often goes undetected by traditional clinical microbiology testing methods, such as automated
MIC testing, and, at present, there is no suitable method for real-
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time identification in the clinical microbiology laboratory (12,
13). The prevalence of hVISA in many geographic regions remains
unknown; however, reports of its occurrence range from 1.2% to
29.2% of MRSA isolates (14–18).
There have been numerous publications on the outcomes of S.
aureus bloodstream infections (BSI) with hVISA versus vancomycin-susceptible S. aureus (VSSA) strains (19–24). Within these
studies, however, pneumonia as a primary source is not prevalent;
the most common sources of BSI were catheters, osteopathic
hardware, or wound infections. Little evidence currently exists
regarding S. aureus resistance or heteroresistance and associated
outcomes specifically in the setting of pneumonia (25). This study
aimed to present a comparative assessment between patients with
hVISA pneumonia and those with VSSA pneumonia, with a focus
on clinical outcomes.
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MATERIALS AND METHODS
Study design and population. This retrospective cohort study was conducted using data from adult patients (age of ⱖ18 years) treated at the
Detroit Medical Center from 2005 to 2014 for clinically defined pneumonia (26, 27). Patients with pneumonia as diagnosed by treating physicians
and with MRSA identified as the causative pathogen were included in the
study, and available isolates from the blood and/or respiratory tract were
used in the analysis. Patients were required to have new or progressive
infiltrates on a chest radiograph as well as at least two of the following signs
and symptoms: cough, purulent sputum, rales/crackles, dyspnea, hypoxemia (ⱕ90% oxygen saturation [SpO2]), temperature alteration (⬎38°C
or ⬍35°C), altered mental status, or white blood cell count of ⬎10,000
cells/mm3 or ⬍4,500 cells/mm3. Patients were matched by age (grouped
as 18 to 45 years, 45 to 75 years, ⬎75 years) and infection/admission year
(within 3 years) at a ratio of 2:1 hVISA to VSSA pneumonias based on the
results of a 48-h modified population analysis profile area under the curve
(PAP-AUC). Patients were excluded from the analysis if they were less
than 18 years of age, if S. aureus was not identified as the causative pathogen, if the vancomycin MICs of their isolates were ⬎2 mg/liter, or if
mortality occurred before anti-MRSA therapy was received for at least 72
h. The Institutional Review Board at Wayne State University approved the
study, and a wavier of informed consent was obtained.
Clinical data, outcome assessments, and definitions. Patient data included the following: demographics, comorbidities, Charlson comorbidity score, location prior to admission, hospitalization history, receipt of
prior antibiotic therapy in the previous 30 days, sequential organ failure
assessment (SOFA) score within 24 h of admission, location at onset of
infection (medical floor versus ICU), type of ICU (medical, surgical, or
trauma/burn), concurrent sites of infection, pharmacokinetic variables
(antibiotic dosing and vancomycin levels), presence of an infectious disease (ID) consult, and anti-MRSA therapies used in treatment. The type of
pneumonia was determined using definitions from the Infectious Diseases Society of America (IDSA) guidelines for community, hospital-acquired, ventilator-associated, and health care-associated pneumonia (28,
29). Outcome parameters included duration of concurrent bacteremia as
applicable, temperature and white blood cell count (WBC) for up to 14
days postdiagnosis of pneumonia, length of hospital stay (LOS), length of
ICU stay, length of mechanical ventilation as applicable, vancomycin failure, and inpatient all-cause as well as MRSA-related mortality. Length of
hospital stay was calculated as total number of calendar days of inpatient
admission as well as postpneumonia length of stay (LOSPNA); similarly,
ICU length of stay was defined as the number of calendar days the patient
was admitted to a dedicated intensive care unit as well as postpneumonia
ICU stay (ICU LOSPNA), defined as the LOS after the diagnosis of pneumonia. Therapy was defined as appropriate if the isolate demonstrated in
vitro susceptibility and was dosed based on institutional guidelines according to renal function, weight, and therapeutic monitoring, as applicable. Vancomycin was not considered appropriate therapy in hVISApositive patients as increased treatment failure and morbidity have been
demonstrated.
Inpatient mortality was defined as expiration of the patient due to any
cause while admitted. Mortality was defined as MRSA related if death
occurred while the patient was bacteremic with MRSA, if death occurred
before documented resolution of pneumonia, or if infection with MRSA
was indicated as the cause of death within the electronic medical records
(eMRs). Vancomycin treatment failure was defined as a composite of
nonresolving signs and symptoms of infection for at least 7 days, a need to
change to a different anti-MRSA agent according to the treating physician,
recurrent MRSA respiratory infection while the patient was hospitalized,
or MRSA-related mortality.
Microbiological and molecular assessment. Microbiological testing
was performed on the first available respiratory and/or blood isolate for
each patient included in the analysis. Susceptibility to vancomycin was
determined by broth microdilution (BMD) in duplicate, in accordance
with the Clinical and Laboratory Standards Institute (CLSI) guidelines, at
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the Anti-Infective Research Laboratory (Detroit, MI) (30). All isolates also
underwent additional testing to determine hVISA status by a modified
48-h PAP-AUC method as previously described by Wooten et al. (31).
Isolates were inoculated at 1 ⫻ 108 CFU/ml on brain heart infusion (BHI)
plates containing increasing concentrations of vancomycin (0, 0.5, 1, 1.5,
2, 3, 4, and 8 mg/liter) using automatic spiral dispensers (Whitley Automated Spiral Plater; Don Whitley Scientific, West Yorkshire, United Kingdom) and incubated at 35°C for 48 h. Subsequent colony counts (log10
CFU/ml) were determined using a laser colony counter (Scan 1200; Interscience, Saint Nom, France) and plotted against vancomycin concentration. The area under the population curve was computed using the trapezoidal method in SigmaPlot (version 10; Systat Software, Inc., San Jose,
CA, USA) and compared to the AUC of the reference strain Mu3 (ATCC
700698). Isolates tested were considered to be hVISA if the PAP-AUC
ratio of the test isolate to Mu3 was ⱖ0.9 (18, 31). The staphylococcal
cassette chromosome mec (SCCmec), USA300 or USA400, and accessory
gene regulator (agr) type as well as the presence of Panton-Valentine
leukocidin (PVL) were determined through multiplex PCR as described
previously (32, 33). agr dysfunction was determined phenotypically by
␦-hemolysin assay (34).
Statistical analysis. Descriptive analysis was performed on patient
characteristics. Dichotomous variables were compared using a chi-square
or Fisher’s exact test, as appropriate, and continuous variables were compared using a Wilcoxon rank sum test or Student’s t test, as appropriate.
All variables with P values of ⱕ0.05 were considered significant. Assuming
a 20% difference in inpatient mortality between hVISA and VSSA patients
at a power of 80% and a two-sided significance level of 0.05 at a 2:1
allocation ratio, the minimum sample size was determined to be 29 hVISA
patients and 58 VSSA patents. Multivariable conditional backward stepwise logistic regression was performed to determine variables independently associated with inpatient mortality. All variables associated with
the outcome of interest upon univariate analysis with a P value of ⱕ0.1 or
determined to be clinically relevant a priori were included in the regression model. Model fit was determined by a Hosmer-Lemeshow goodnessof-fit test with a P value of ⬎0.05. Statistical analysis was performed using
IBM SPSS, version 21.0 (IBM Corp., Armonk, NY).

RESULTS

A total of 87 patients, representing 29 (33.3%) hVISA and 58
(66.7%) VSSA cases of pneumonia, were included in the final
analysis, meeting the minimum sample size determined a priori.
There were no significant differences in terms of baseline characteristics between hVISA and VSSA patients with the noted exception of estimated glomerular filtration rate (eGFR), which was
significantly lower in the hVISA cohort (Table 1). Patients in the
hVISA cohort had a median baseline eGFR of 60.0 ml/min/1.73
m2 (interquartile ratio [IQR], 36.5 to 100.0 ml/min/1.73 m2) while
VSSA patients had a median baseline eGFR of 86.0 ml/min/1.73
m2 (IQR, 60.0 to 115.5 ml/min/1.73 m2) (P ⫽ 0.022). Severity of
illness as measured by SOFA scores was numerically higher in the
hVISA cohort than in the VSSA cohort (7.0 [IQR, 5.0 to 8.0]
versus 5 [IQR, 3.0 to 8.0]). S. aureus was isolated more commonly
from induced sputum (n ⫽ 46; 52.9%) than from bronchoalveolar lavage (BAL) fluid (n ⫽ 13; 14.9%), and concurrent bacteremia
was common (n ⫽ 79; 90.1%). There were no significant differences in concurrent sites of infection between hVISA and VSSA
patients.
Vancomycin was the empirical MRSA agent for all patients
included in the analysis. There was no difference in the loading
doses between the two groups. Among the hVISA cohort, loading
doses were given to 20 (69.0%) patients at a mean dose of 22.0 ⫾
4.7 mg/kg total body weight. A total of 41 (70.1%) patients with
VSSA received a loading dose at a mean of 22.4 ⫾ 4.5 mg/kg total
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TABLE 1 Baseline characteristics of hVISA and VSSA patients
Value for the cohort
Parameter

hVISA (n ⫽ 29)

VSSA (n ⫽ 58)

P value

Median age (yr [IQR])
Median wt (kg [IQR])
Median Charlson score (IQR)
Median SOFA score (IQR)b
No. (%) of female patients
No. (%) of African American patients

63.0 (56.0–76.0)
70.0 (63.5–87.5)
5 (2.5–7.0)
7.0 (5.0–8.0)
10 (34.5)
21 (72.4)

59.00 (50.0–68.25)
69.9 (60.4–79.7)
5 (2.0–7.0)
5 (3.0–8.0)
24 (41.4)
40 (69.0)

0.117
0.595
0.995
0.092
0.534
0.907

Clinical factors (no. of patients [%])
Diabetes
History of CVA
Any respiratory pathology
HIV/AIDS
Liver disease
Intravenous drug use
Hemodialysis

10 (34.5)
7 (24.1)
13 (44.8)
2 (6.9)
2 (6.9)
8 (27.6)
3 (10.3)

22 (37.9)
16 (27.6)
33 (56.9)
3 (5.2)
7 (12.1)
11 (19.0)
4 (6.9)

0.753
0.731
0.241
0.745
0.455
0.359
0.577

eGFR (median [IQR])
Baseline
At start of antimicrobial treatment

60.0 (36.5–100.0)
31.5 (17.3–68.0)

86.0 (60.0–115.5)
62.0 (38.0–96.5)

0.022
0.013

15 (51.7)
7 (24.1)

32 (55.2)
7 (12.1)

0.761
0.149

19 (65.5)
8 (27.6)

35 (60.3)
15 (25.9)

0.851
1.000

a

Prior hospitalization (no. of patients [%])
Antibiotic use in the last 30 days (no. of patients [%])
Admission data (no. of patients [%])
Home
SNF

a
IQR, interquartile range; SOFA, sequential organ failure assessment; CVA, cerebrovascular accident; HIV, human immunodeficiency virus; eGFR, estimated glomerular filtration
rate; SNF, skilled nursing facility.
b
First 24 h after hospital admission.

body weight. Additionally, maintenance doses were not significantly different (14.8 ⫾ 4.8 mg/kg for the hVISA cohort versus
15.2 ⫾ 4.3 mg/kg for the VSSA cohort). Initial steady-state vancomycin levels often did not reach target trough serum vancomycin concentrations of at least 15 mg/liter (42.3% versus 59.6%,
respectively; P ⫽ 0.148) (35). Patients were switched from vancomycin to another MRSA agent that was appropriate based on the
above definition more commonly in the hVISA cohort (48.3%
versus 34.5% for the VSSA cohort; P ⫽ 0.214) at a median time of

66.6 h (IQR, 32.3 to 109.2 h). Linezolid was the most common
MRSA agent that patients were switched to (8/29, or 29.6%, for
the hVISA cohort versus 12/58, or 20.7%, for the VSSA cohort;
P ⫽ 0.416). Isolates available for vancomycin MIC testing were
collected from blood (n ⫽ 69; 79.3%), the respiratory tract (n ⫽
12; 13.8%), or both (n ⫽ 6; 6.9%) (Fig. 1). Although there was a
20% difference (95% confidence interval [CI], 13.8% to 31.1%) in
vancomycin failure between the hVISA and VSSA cohorts (79.3%
versus 58.6%, respectively; P ⫽ 0.056), this was not significant.

FIG 1 Vancomycin MIC (mg/liter) frequency and distribution by broth microdilution.
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TABLE 2 Clinical features and course of hVISA versus VSSA infection
Value for the cohort
Characteristic

hVISA (n ⫽ 29)

VSSA (n ⫽ 58)

P value

Type of pneumonia (no. of patients [%])
Community acquired
Health care associated
Hospital acquired
Ventilator associated

6 (20.7)
12 (41.4)
5 (17.2)
6 (20.7)

12 (20.7)
24 (41.4)
8 (13.7)
14 (24.1)

1.000
1.000
0.753
0.792

Antibiotic therapy (no. of patients [%])
Vancomycin
Linezolid
Ceftaroline
TMP/SMX

15 (51.7)
8 (29.6)
3 (10.3)
1 (3.4)

38 (65.5)
12 (20.7)
3 (5.2)
2 (3.4)

0.214
0.416
0.395
1.000

Median time (h) to change in therapy (IQR)
Median (IQR) LOS (days)b
Median (IQR) LOSPNA (days)b
ID consult (no. of patients [%])
Concurrent bacteremia (no. of patients [%])
Median (IQR) duration of bacteremia (days)
Presence of concurrent sites of infection (no. of patients [%])
Skin/soft tissue
Deep abscess
Bone/joint
Infective endocarditis
Unknown

66.6 (32.3–109.2)
17.5 (11.0–30.5)
13 (7–24)
16 (55.2)
27 (93.1)
2 (1–5)

72.8 (38.7–160.4)
17.5 (11.0–35.8)
11 (6–18)
34 (58.6)
52 (89.7)
2 (1–5)

0.263
0.554
0.797
0.717
0.742
0.901

7 (24.1)
1 (3.4)
2 (6.9)
2 (6.9)
2 (6.9)

8 (13.8)
0 (0.0)
1 (1.7)
2 (3.4)
10 (17.2)

0.229
0.155
0.213
0.469
0.187

ICU admission by type (no. of patients [%])
Burn/trauma
Medical
Surgical

23 (79.3)
6 (26.1)
15 (65.2)
2 (8.7)

40 (70.7)
5 (12.5)
31 (77.5)
5 (12.5)

0.390
0.187
0.379
1.000

Median (IQR) ICU LOS (days)b
Mechanical ventilation (any) (no. of patients [%])
Presence of S. aureus isolate type (no. of patients [%])
PVL positive
USA300
SCCmec type II
agr group II
agr dysfunction

12 (5.5–22.5)
18 (62.1)

13 (5.0–25.0)
37 (63.8)

0.725
0.875

6 (20.7)
6 (20.7)
12 (41.4)
16 (55.2)
12 (41.4)

17 (29.3)
16 (27.6)
25 (43.1)
25 (43.1)
19 (32.8)

0.390
0.485
0.878
0.288
0.429

5 (17.2)
5 (17.2)
1 (3.4)
2 (6.9)

6 (10.3)
5 (8.6)
7 (12.1)
4 (6.9)

0.642
0.362
0.190
1.000

a

Presence of other respiratory pathogens (no. of patients [%])
Acinetobacter spp.
Pseudomonas spp.
Klebsiella spp.
Streptococcal spp.
a

IQR, interquartile range; LOS, length of stay; LOSPNA, length of stay postdiagnosis of pneumonia; ICU, intensive care unit; PVL, Panton-Valentine leukocidin; TMP/SMX,
trimethoprim-sulfamethoxazole.
b
Censored for inpatient mortality.

Patients in both the hVISA and VSSA cohorts had a median
length of stay of 17.5 days (censored for inpatient mortality).
Patients in the hVISA cohort had a longer length of stay before
diagnosis of pneumonia (6.5 days for the hVISA cohort versus
2 days for the VSSA cohort; P ⫽ 0.134). Length of stay postpneumonia diagnosis (LOSPNA) was shorter in the hVISA cohort (14.0 days versus 15.5 days for the VSSA cohort; P ⫽
0.902) until censored for inpatient mortality (20.0 days versus
16.5 days, respectively; P ⫽ 0.631). ICU admissions occurred in
23 (79.3%) hVISA patients and in 40 (70.7%) VSSA patients
(Table 2); there was no difference in distributions of the type of
ICU (burn/trauma versus medical versus surgical). In addition
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there was no difference in the incidence of mechanical ventilation or ID consultations. More patients in the hVISA cohort
presented with a body temperature of less than 36.0°C (24.1%
versus 10.3% for the VSSA cohort; P ⫽ 0.089). More patients in
the VSSA cohort achieved normalized WBC measurements
within 14 days of pneumonia onset (51.7% for the VSSA cohort
versus 37.9% for the hVISA cohort; P ⫽ 0.224). Additionally,
there were no differences in molecular characteristics, including the presence of SCCmec type II (41.1% for the hVISA cohort versus 43.1% for the VSSA cohort), USA300 (20.7% for
the hVISA cohort versus 27.6% for the VSSA cohort), PVL
(20.7% for the hVISA cohort versus 29.3% for the VSSA co-
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TABLE 3 Univariate analysis of clinical features associated with inpatient mortality
Value for the group
Parameter

Nonsurvivors (n ⫽ 27)

Survivors (n ⫽ 60)

P value

Median (IQR) age (yr)
Median SOFA score (IQR)
Median Charlson score (IQR)
No. (%) of female patients
Clinical factors (no. of patients [%])
Diabetes
History of CVA
Any respiratory pathology
HIV/AIDS
Liver disease
Intravenous drug use
Acute kidney injury
Hemodialysis

65.0 (56.0–80.0)
8 (6–9)
6 (4–7)
8 (29.6)

59.0 (56.0–80.0)
5 (3–7)
5 (2–7)
26 (43.3)

0.132
0.001
0.115
0.226

10 (37.0)
7 (25.9)
14 (51.9)
2 (7.4)
3 (11.1)
6 (22.2)
8 (29.6)
1 (3.7)

22 (36.7)
16 (26.7)
26 (43.3)
3 (5.0)
6 (10.0)
13 (21.7)
31 (51.7)
6 (10.0)

0.974
0.942
0.635
0.655
0.875
0.952
0.152
0.318

11 (40.7)
2 (7.4)
2 (7.4)

36 (60.0)
11 (18.3)
10 (16.7)

0.095
0.396
0.247

11 (45.8)
14 (51.9)

31 (57.4)
39 (65.0)

0.344
0.245

11 (40.7)
25 (92.6)
3 (1–6)

40 (66.7)
54 (90.0)
2 (1–5)

0.023
0.207
0.717

4 (14.8)
0 (0.0)
2 (7.4)
1 (3.7)
4 (14.8)

11 (18.3)
1 (1.7)
2 (3.3)
2 (3.3)
8 (13.3)

0.688
0.500
0.401
0.930
0.853

a

No. (%) of patients with prior hospitalization
Antibiotic use in the last 30 days (no. of patients [%])
Previous vancomycin treatment (30 days)
Vancomycin therapy (no. of patients [%])
Vancomycin trough of ⬍15 mg/liter
No change in antibiotic therapy
ID consult (no. of patients [%])
Concurrent bacteremia (no. of patients [%])
Median (IQR) duration of bacteremia (days)
Presence of concurrent sites of infection (no. of patients [%])
Skin/soft tissue
Deep abscess
Infective endocarditis
Bone/joint
Unknown
ICU admission (no. of patients [%])
No. (%) of patients receiving mechanical ventilation (any)
Presence of other respiratory pathogens (no. of patients [%])
Acinetobacter spp.
Pseudomonas spp.
Klebsiella spp.
Streptococcal spp.

23 (85.2)
21 (77.8)

41 (63.8)
34 (56.7)

0.099
0.059

4 (14.8)
2 (7.4)
0 (0.0)
1 (3.7)

7 (11.7)
8 (13.3)
8 (13.3)
8 (8.3)

0.683
0.423
0.046
0.430

Presence of MRSA isolate type (no. of patients [%])
hVISA phenotype
VAN MIC of 2 mg/liter (BMD)
SCCmec type II
PVL positive
USA300
agr type II
agr dysfunction

13 (48.1)
4 (15.4)
13 (48.1)
13 (48.1)
8 (29.6)
14 (51.9)
8 (29.6)

14 (23.3)
5 (8.8)
30 (50.0)
10 (16.7)
14 (23.3)
27 (45.0)
23 (38.3)

0.049
0.501
0.873
0.002
0.532
0.554
0.433

a
IQR, interquartile range; SOFA, sequential organ failure assessment; CVA, cerebrovascular accident; HIV, human immunodeficiency virus; MRSA, methicillin-resistant S. aureus;
hVISA, heterogeneous vancomycin-intermediate S. aureus.

hort), or agr group II (55.2% for the hVISA cohort versus
43.1% for the VSSA cohort) (Table 2).
Inpatient mortality occurred in 27 (31.0%) patients. There
were more cases of inpatient mortality among the hVISA cohort
(44.8% versus 24.1% for the VSSA cohort; P ⫽ 0.049). In the
subgroup of patients with respiratory cultures positive for MRSA
(n ⫽ 60), inpatient mortality was numerically higher in the hVISA
cohort (40.0% versus 22.5% for the VSSA cohort; P ⫽ 0.162).
Variables significantly associated with inpatient mortality upon
univariate analysis include the presence of the hVISA phenotype,
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presence of PVL, higher SOFA score, ICU stay, mechanical ventilation, higher Charlson comorbidity score, history of prior hospitalization, ID consult, and acute kidney injury at initiation of antibiotics (Table 3). Upon multivariable backward stepwise
conditional logistic regression (Table 4), variables independently
associated with inpatient mortality included SOFA score (adjusted odds ratio [aOR], 1.36; 95% CI, 1.08 to 1.70), ID consult
(aOR, 0.35; 95% CI, 0.11 to 1.13), and hVISA phenotype (aOR,
3.95; 95% CI, 1.18 to 13.21). The variables of mechanical ventilation and ICU stay were not entered into the final model due to
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TABLE 4 Multivariable logistic regression for risk factors associated
with inpatient mortality
Characteristica

Unadjusted OR (95% CI)

Adjusted OR (95% CI)

hVISA phenotype
PVL positive
ID consult
SOFA score

2.55 (0.99–6.59)
1.39 (1.45–11.08)
0.37 (0.15–0.94)
1.36 (1.14–1.65)

3.95 (1.18–13.21)
6.63 (1.79–24.64)
0.35 (0.11–1.13)
1.36 (1.08–1.70)

a

hVISA, heterogeneous vancomycin-intermediate S. aureus; PVL, Panton-Valentine
leukocidin; ID consult, infectious disease consultation; SOFA, sequential organ failure
assessment.

colinearity with the SOFA score. A Hosmer-Lemeshow goodnessof-fit test demonstrated good overall model fit, with a P value of
0.559.
DISCUSSION

In this single-center cohort study of outcomes of patients with
hVISA pneumonia compared to those with VSSA pneumonia,
the presence of the hVISA phenotype was found to be an independent predictor of inpatient mortality after adjustment for
patient severity. This is unique from previously published
studies that compared outcomes in patients with VSSA infection to those with hVISA infection in that it focuses on patients
with pneumonia, a population known to have high rates of
morbidity and mortality. There remains considerable debate
regarding the pathogenicity of hVISA compared to that of
VSSA, with reports of increased antibiotic failure and longer
duration of bacteremia for hVISA strains but conflicting results
regarding mortality (19, 21, 22, 24, 36, 37). Two observational
studies have reported increased mortality among patients with
hVISA infections; however, these studies were purely descriptive in nature, and neither confirmed the hVISA phenotype by
PAP-AUC (36, 37). Subsequently, Maor et al. conducted a casecontrol study with 27 hVISA patients and 223 VSSA patients
and found no difference in overall mortality rates (51% versus
46%, respectively; P ⫽ 0.6) or infection-attributable mortality
rates (44% versus 36%, respectively; P ⫽ 0.4) (19). The source
of bacteremia was not fully detailed, and the report mentioned
only that the rates of pneumonia were similar in both groups.
Additionally, our laboratory has previously published a study
on the clinical outcomes of hVISA versus VSSA BSI and found
a numerically higher rate of MRSA-related mortality in the
hVISA cohort, but the difference was not significant (21% versus 10% for the VSSA cohort; P ⫽ 0.081). In this study, the
most common primary diagnosis was infective endocarditis
(39.9%), followed by catheter-related infections (24.6%), with
pneumonia representing 8.2% of patients. In 2011, van Hal et
al. reported that the presence of the hVISA phenotype was
independently associated with decreased mortality among 409
MRSA BSI cases (11.5% hVISA infections) resembling the
ST239 MRSA III clone (22). Overall mortality was reported to
be 29.0%, with hVISA mortality significantly lower at 10.9%, a
stark contrast to the 44.8% inpatient mortality in our study.
The diagnosis of pneumonia was an independent predictor of
mortality, and it is important to note that only 2 (4.3%) hVISA
patients, in contrast to 50 (14.2%) VSSA patients, had a principal diagnosis of pneumonia.
The majority of the literature comparing hVISA and VSSA
infections is retrospective in nature and focuses on S. aureus BSI
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from a variety of primary sources. It is clear from previous literature on MRSA BSI that the sources of hVISA infections tend to
differ from those of VSSA infections. Isolates demonstrating the
hVISA phenotype have more commonly been isolated from central intravenous line and wound infections (23, 38). MRSA is a
frequent cause of pneumonia and has been consistently reported
to be associated with significant morbidity and mortality. In 2012
Mendes et al. evaluated the clinical characteristics of MRSA isolates recovered from an international prospective phase IV pneumonia trial (39). Among the 434 MRSA isolates tested, 14.5%
were determined to be hVISA by the macromethod Etest (bioMérieux, Marcy l’Etoile, France). In a retrospective observational
study of 251 critically ill patients with MRSA-positive HCAP,
HAP, or VAP, Haque et al. reported that hVISA accounted for
15.9% of infections (40). The 28-day all-cause mortality was
37.1%. hVISA was not significantly associated with mortality;
however, this was not a primary outcome metric for the study.
Our current study is unique with regard to its focus on clinical
outcomes in patients with hVISA pneumonia compared to those
in patients with VSSA pneumonia. Although baseline and clinical
characteristics were balanced between the two groups, patients
with hVISA pneumonia experienced a significantly higher rate of
mortality. This was in spite of the fact that vancomycin treatment
failure rates were not significantly different. The occurrence of
vancomycin failure in the hVISA cohort was similar to that in our
previous analysis (82% in the previous study versus 79% in the
present study) but considerably higher in the VSSA cohort (33%
in the previous study versus 59% in the present study) (20). This
difference was largely driven by a change in antibiotic therapy in
the VSSA cohort.
Delayed appropriate antibiotic therapy (greater than 24 to 48 h
after initial diagnosis) may help to explain the current finding of
increased mortality in the hVISA cohort. Previous publications
have related delayed appropriate therapy in the setting of pneumonia to increased mortality (5, 41). In a recent publication by
Inchai et al., late antibiotic therapy (⬎24 h) was associated with a
hazard ratio of 2.23 (95% CI, 1.12 to 4.45; P ⫽ 0.022) among a
single-center cohort of patients diagnosed with VAP (6). In contrast, DeRyke et al. reported no significant difference in inpatient
mortality rates among VAP patients that received timely versus
delayed appropriate antibiotic therapy (42). Evidence in community-acquired pneumonia (CAP) also fails to demonstrate consistent conclusions (41, 43, 44). Timely administration of appropriate antibiotics has been previously demonstrated in MRSA BSI
(45). In patients with hospital-acquired S. aureus BSI, delays in
appropriate antibiotic therapy of greater than 44.8 h resulted in a
3-fold-increased odds of infection-related mortality. In our current hVISA cohort, over 90% of patients had positive blood cultures, and the median time to change in antibiotic therapy was
over 60 h, which is over the proposed breakpoint of 44.8 h established by Lodise et al. To our knowledge there is no available
literature that directly addresses the timing of appropriate antibiotic therapy in hVISA versus VSSA infection; therefore, literature
from MRSA BSI has been extrapolated to the current study.
Additionally, our current sample size is not powered to adequately
determine if delayed appropriate antibiotic therapy is an independent predictor of inpatient mortality; however, this cannot be
ruled out and deserves further future investigation.
Several isolate-related characteristics have also been associated
with the presence of the hVISA phenotype, increased mortality, or
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both. In the current study, patients with hVISA infection were
more likely to have an elevated vancomycin MIC (2 mg/liter by
BMD) than patients with VSSA infection. This has been demonstrated to be the case in previous hVISA studies (20, 46). Additionally, elevated vancomycin MICs have been linked to increased
mortality in MRSA pneumonia (47). In the current study, there
was a strong association between PVL positivity and increased
mortality. The presence of PVL has been inconsistently associated
with mortality (48, 49). In fact, in the study by Haque et al., PVL
negativity was associated with increased mortality on univariate
analysis but was not an independent predictor of mortality (25).
Dysfunction of agr was not associated with the hVISA phenotype
although this association has been demonstrated in the past (50).
Also of note, agr dysfunction was not associated with worse outcomes or increased mortality, as has been previously demonstrated (34).
This study has several limitations, namely, those associated
with retrospective single-center studies. Efforts were made to control for confounding variables through matching on relevant parameters. Additionally, physiological parameters were well balanced between the cohorts. We cannot exclude the possibility that
confounding still occurred, however, as the small sample size precludes an extensive analysis. In patients who were bacteremic,
every attempt was made to secure both respiratory and blood isolates. Due to the retrospective nature of the research, however, this
was unachievable for some patients, and PAP-AUC and molecular
analysis were carried out on the available isolate. Without pulsefield gel electrophoresis it is not possible to definitely determine if
this study represents the impact of a predominant clonal strain of
hVISA; however, through the molecular testing that was completed, there is evidence of a diversity of characteristics among the
available strains. Although the rate of concurrent bacteremia is
significantly higher in this study than that in a recent publication
by Shorr et al. (51), this is due to the limitations listed above.
Additionally, since the rates of bacteremia were not significantly
different in the two groups studied, they likely represent a nondifferential bias. Lastly, the diagnosis of pneumonia was based on
clinically defined criteria as described above; cases may have been
missed in the eMRs.
In conclusion, in patients diagnosed with MRSA pneumonia,
the presence of the hVISA phenotype was independently associated with increased inpatient mortality. Patients with hVISA
pneumonia were more likely to have an elevated vancomycin MIC
by BMD, which may contribute to this increased mortality. The
current findings with respect to delayed appropriate therapy in
hVISA versus VSSA infection are exploratory and deserve further,
focused investigation.
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